Market Overview

Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue

Share:
Related NEOG
Earnings Scheduled For September 27, 2016
25 Stocks Which Rallied Four Days, Then Sold Off Yesterday
Neogen Corporation's (NEOG) CEO Jim Herbert on Q1 2017 Results - Earnings Call Transcript (Seeking Alpha)
Related VIVO
Sectors and Stocks To Watch If Hillary Clinton Is Elected
UPDATE: Meridian Bioscience Announces Investment in Oasis Diagnostics; Terms Not Disclosed

Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of revenue.

The trailing-twelve-month revenue at Neogen (NASDAQ: NEOG) is $179.10 million. Neogen had $61.33 million in total cash for the latest quarter.

The trailing-twelve-month revenue at Meridian Bioscience (NASDAQ: VIVO) is $169.11 million. Meridian Bioscience's PEG ratio is 1.37.

The trailing-twelve-month revenue at Abaxis (NASDAQ: ABAX) is $156.60 million. Abaxis's ROE for the same period is 7.97%.

The trailing-twelve-month revenue at Quidel (NASDAQ: QDEL) is $136.97 million. Quidel had $21.56 million in total cash for the latest quarter.

Posted-In: Diagnostic Substances Industry Highest Revenue small-capTrading Ideas

 

Related Articles (ABAX + NEOG)

View Comments and Join the Discussion!